GLP-1 Drugs and Surgery: Do You Have to Stop Before a Procedure?

TL;DR: If you take a GLP-1 drug such as Ozempic, Wegovy, Mounjaro, or Zepbound and you have surgery, a colonoscopy, or another procedure under anesthesia or sedation coming up, the current answer is that most people can safely continue it. In 2024, five medical societies, including the anesthesiologists, the gastroenterologists, and the bariatric surgeons, published joint guidance that moved away from routinely stopping these drugs and toward an individualized decision made by your care team. This replaced a 2023 recommendation to hold the drug for about a week, which is out of date. The concern is well founded: GLP-1 drugs slow how fast the stomach empties, so the stomach can still hold food or liquid after a normal fast, which raises the risk of breathing stomach contents into the lungs while you are sedated. Endoscopy studies confirm the retained contents, though frank aspiration is uncommon. The right move is to tell your whole team well ahead of time, follow their specific plan, and never stop the drug on your own, particularly if you take it for diabetes.

Do I need to stop my GLP-1 before surgery?

For most people, no. The guidance that governs this in 2026 comes from a joint statement published in October 2024 by five medical societies: the anesthesiologists, the gastroenterologists, the bariatric surgeons, and two perioperative and endoscopic surgery groups.¹ Its headline is that most patients can safely continue their GLP-1 drug through a procedure, and that the decision should be individualized rather than governed by a single rule that applies to everyone.

That is a meaningful correction to what many people were told earlier. For a while, the working assumption was that anyone on a weekly GLP-1 should hold it for about a week before any procedure. That is no longer the default. The current approach is to weigh each person's situation, and to use targeted precautions when needed rather than routinely stopping a medication that is often doing important work for weight, blood sugar, and heart risk.

The decision is not yours to make alone, and it is not the anesthesiologist's alone either. It is a shared one, made by you together with your surgeon or proceduralist, your anesthesia team, and the clinician who prescribes the drug. Your job is to make sure every one of them knows you take it, and to follow the plan they build.

Why does a weight or diabetes drug matter for anesthesia?

GLP-1 drugs slow how quickly the stomach empties its contents into the intestine. That is part of how they work: a fuller stomach for longer helps quiet appetite. The side effect of that mechanism is that the stomach can still hold food or liquid even after the standard pre-procedure fast, when it would normally be empty. Tirzepatide, the drug in Mounjaro and Zepbound, acts on two gut hormones rather than one, but it slows stomach emptying in the same way, so the same concern applies to it.

That matters for anesthesia because of a complication called aspiration. Under general anesthesia or deep sedation, the reflexes that keep stomach contents from coming back up and entering the airway are blunted. If the stomach is not empty, those contents can be regurgitated and breathed into the lungs, which can cause a serious pneumonia. A retained-content stomach is the setup for that event.

The evidence that GLP-1 users have retained contents is consistent. When patients on these drugs come in for an upper endoscopy, where the doctor can see directly into the stomach, those on a GLP-1 are several times more likely to have food or liquid still present despite following the fasting instructions.² Studies using an ultrasound of the stomach before procedures have found the same pattern.³

Here is the part that keeps the concern in proportion. Retained contents are more common on a GLP-1, and they do lead to more procedures being paused, cut short, or rescheduled. But frank aspiration, the event where contents enter the lungs, remains uncommon in absolute terms; several analyses have found no large increase in aspiration itself. So the honest framing is that GLP-1 drugs raise a risk that is consistent and reproducible, but that the feared complication is still rare and, with the right precautions, usually manageable. The response is to manage the risk with sensible precautions.

What changed between 2023 and now?

The guidance moved in a short window, which is why patients hear conflicting advice.

In June 2023, the anesthesiologists issued their first consensus statement on GLP-1 drugs and procedures.⁴ Because the evidence at the time was thin, mostly case reports, the statement was cautious: for daily formulations, consider holding the drug on the day of the procedure; for weekly formulations, consider holding it for about a week beforehand. That is the source of the "stop it for a week" advice many people still repeat.

By late 2024, more data had accumulated, and the concern had grown that routinely stopping a GLP-1 carried its own costs: worse blood sugar control, lost momentum on weight, cancelled or delayed procedures, and the practical burden of interrupting a medication for millions of people. So the October 2024 multisociety guidance replaced the blanket hold with an individualized approach. It is the more current and more nuanced framework, and as of 2026 it remains the standard; later expert consensus statements have reinforced the same direction rather than reversing it, though some 2025 statements favor a stricter preoperative fasting window while still continuing the drug.

If you were told at some point to stop your GLP-1 for a week before a procedure, that advice was not wrong when it was given. It has simply been updated. What you should follow now is whatever your current care team advises under the newer framework, because they can account for your specific dose, timing, and symptoms.

How does the care team decide?

The 2024 guidance replaces one rule with a set of judgments. A few features raise the concern that the stomach may be slow to empty, and push toward more caution:

• Being in the dose-escalation phase, where the dose is still being raised, rather than on a stable maintenance dose.
• Higher doses of the drug.
• Active gut symptoms such as nausea, vomiting, bloating, or a feeling of fullness, which suggest the stomach is already emptying slowly.

When those features are present, or when there is any uncertainty, the team has options that do not require stopping the drug for a week:

• A clear-liquid diet for about 24 hours before the procedure, which lets the stomach empty while the medication continues.
• A point-of-care ultrasound of the stomach on the day of the procedure, to look directly for retained contents when there is concern. This is a useful tool where it is available, though not every setting has someone trained to perform it.
• Treating the patient as though the stomach is full, using anesthesia techniques designed to protect the airway, such as a rapid-sequence induction, if contents are suspected or confirmed. This is the same approach used for anyone with slow stomach emptying.

The guidance also makes a point that is easy to miss: it warns against reflexively holding the drug only for patients who take it for weight, since that singles out one group and can reflect bias rather than medical judgment. The risk assessment should be the same regardless of why the drug was prescribed.

What should I do before a procedure?

Your part is simple and important.

First, tell everyone involved that you take a GLP-1, and do it well ahead of time rather than on the morning of the procedure. That means your surgeon or the doctor performing the procedure, the anesthesia team, and the clinician who prescribes the drug. The name of the drug, the dose, when you last took it, and whether you have had any nausea or fullness are all useful.

Second, do not stop the drug on your own. This is critical if you take it for type 2 diabetes, because stopping a diabetes medication without a plan can send your blood sugar in the wrong direction; any pause needs a glucose-management plan from your care team. Even for weight, the decision to hold or continue belongs with the team, because they may prefer to continue it with precautions.

Third, follow the specific instructions you are given, which may include continuing the drug, a day of clear liquids, an earlier check on the day, or, in some cases, holding a dose. Different teams and different procedures call for different plans, and yours is built around your situation.

This applies broadly to procedures done under anesthesia or sedation: operations, and also gastrointestinal endoscopy such as a colonoscopy or upper endoscopy, where retained food can force an incomplete or aborted exam. If you are booked for any of these, the same conversation applies.

Guidance from the Clinic

"The advice on this changed fast, so patients come in with a rule they were given a year or two ago that no longer holds. What I want people to understand is that we are no longer in the business of automatically stopping these drugs for a week before every procedure. The current guidance is that most people can continue, and that we tailor the plan. My job is to know your dose, whether you are still going up on it, and whether your stomach has been giving you trouble, and then to talk to your surgeon and your anesthesiologist so we make one coordinated decision instead of three separate guesses. The risk we are managing is present but uncommon, and it is very manageable when everyone knows what you are taking. The mistake I want to prevent is a patient stopping a diabetes drug on their own before surgery, because that trades a small, manageable risk for a blood-sugar problem nobody planned for."

Related at Fishtown Medicine

• Ozempic, Wegovy, and Mounjaro: The GLP-1 Strategy - how these drugs are prescribed and managed here
• Tirzepatide (Zepbound, Mounjaro) - the dual agonist, and how its dosing works
• Medical Weight Loss and Body Composition - where GLP-1 drugs fit in a weight plan
• Ozempic vs Metformin - choosing among metabolic drugs

Scientific References

1. American Society of Anesthesiologists, American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, International Society of Perioperative Care of Patients with Obesity, and Society of American Gastrointestinal and Endoscopic Surgeons. "Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period." Clinical Gastroenterology and Hepatology; Surgical Endoscopy; Surgery for Obesity and Related Diseases. 2024.
2. Silveira SQ, da Silva LM, Abib ADCV, de Moura DTH, de Moura EGH, Santos LB, Mizubuti GB. "Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy." Journal of Clinical Anesthesia. 2023;87:111091.
3. Sherwin M, Hamburger J, Katz D, DeMaria S. "Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide." Canadian Journal of Anesthesia. 2023;70(8):1300-1306.
4. American Society of Anesthesiologists. "American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 Receptor Agonists." June 29, 2023.